Shockwave Medical Continues to Execute on Its Growth Plans
Owning small-cap companies can be a little nerve-racking, especially if it's a medical device company that's waiting on FDA approval. For Shockwave Medical (NASDAQ: SWAV) investors, the wait is over. It received the go-ahead from the FDA for its coronary artery disease device this past month. On a Fool Live episode recorded on Feb. 18, Fool contributor Brian Feroldi discusses the impact this approval could have going forward and dives into the company's most recent financial results.
Source Fool.com
